- Home
- RCEL vs DRTS Comparison
RCEL vs DRTS Comparison
Compare RCEL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- DRTS
- Stock Information
- Founded
- RCEL N/A
- DRTS 2015
- Country
- RCEL United States
- DRTS Israel
- Employees
- RCEL N/A
- DRTS N/A
- Industry
- RCEL Medical/Dental Instruments
- DRTS Medical/Dental Instruments
- Sector
- RCEL Health Care
- DRTS Health Care
- Exchange
- RCEL Nasdaq
- DRTS Nasdaq
- Market Cap
- RCEL 240.6M
- DRTS 211.7M
- IPO Year
- RCEL N/A
- DRTS N/A
- Fundamental
- Price
- RCEL $6.97
- DRTS $2.95
- Analyst Decision
- RCEL Strong Buy
- DRTS Strong Buy
- Analyst Count
- RCEL 4
- DRTS 2
- Target Price
- RCEL $17.25
- DRTS $8.00
- AVG Volume (30 Days)
- RCEL 197.1K
- DRTS 27.4K
- Earning Date
- RCEL 05-08-2025
- DRTS 05-19-2025
- Dividend Yield
- RCEL N/A
- DRTS N/A
- EPS Growth
- RCEL N/A
- DRTS N/A
- EPS
- RCEL N/A
- DRTS N/A
- Revenue
- RCEL $71,661,000.00
- DRTS N/A
- Revenue This Year
- RCEL $62.33
- DRTS N/A
- Revenue Next Year
- RCEL $30.59
- DRTS N/A
- P/E Ratio
- RCEL N/A
- DRTS N/A
- Revenue Growth
- RCEL 41.35
- DRTS N/A
- 52 Week Low
- RCEL $6.90
- DRTS $1.75
- 52 Week High
- RCEL $14.16
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- RCEL 28.06
- DRTS 68.40
- Support Level
- RCEL $9.50
- DRTS $2.50
- Resistance Level
- RCEL $9.85
- DRTS $2.96
- Average True Range (ATR)
- RCEL 0.53
- DRTS 0.15
- MACD
- RCEL -0.20
- DRTS 0.04
- Stochastic Oscillator
- RCEL 10.03
- DRTS 97.83
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.